\-\ Texto\\:\\ \ \(0\)\
\-\ pe\\ was\\ remarkable\\ for\\ enlarged\\,\\ painless\\,\\ smooth\\ thyroid\\ gland\\ without\\ palpable\\ nodules\\ and\\ normal\\ dtrs\\.\\ \\ patient\\ had\\ mildly\\ coarse\\ facial\\ features\\ \\(including\\ brow\\,\\ jaw\\,\\ and\\ nose\\)\\.\\ \\ no\\ visual\\ field\\ defects\\.\\ remainder\\ of\\ physical\\ exam\\ normal\\.\ \(0\)\
\-\ serum\\ ft4\\,\\ total\\ t3\\,\\ and\\ tsh\\ concentrations\\ were\\ all\\ elevated\\:\ \(0\)\
\-\ free\\ t4\\ \\:\\ 3\\.1\\	total\\ t3\\ \\:\\ 427\\	tsh\\ \\:\\ 5\\.58\\	\ \(0\)\
\-\ hgh\\ \\:\\ 1\\.3\\ \\	igf\\-1\\ \\:\\ 362\\	alpha\\ subunit\\ \\:\\ 3\\.6\\	\ \(0\)\
\-\ oral\\ glucose\\ tolerance\\ test\\ failed\\ to\\ suppress\\ gh\\ suggesting\\ unregulated\\ secretion\\ of\\ gh\\.\\ \ \(0\)\
\-\ acth\\,\\ prolactin\\,\\ fsh\\,\\ and\\ lh\\ all\\ within\\ normal\\ limits\ \(0\)\
\-\ surgical\\ resection\\ is\\ the\\ treatment\\ of\\ choice\\ for\\ pituitary\\ adenomas\\,\\ however\\,\\ somatostatin\\ analogs\\ can\\ be\\ used\\ to\\ effectively\\ reduce\\ autonomous\\ secretion\\ of\\ pituitary\\ hormones\\,\\ as\\ well\\ decrease\\ the\\ size\\ of\\ the\\ adenomas\\ by\\ approximately\\ 50\\%\\.\\ \\ due\\ to\\ the\\ invasive\\ nature\\ of\\ this\\ macroadenoma\\,\\ octreotide\\ therapy\\ was\\ initiated\\ in\\ this\\ patient\\ to\\ facilitate\\ a\\ more\\ optimal\\ surgical\\ outcome\\.\ \(0\)\
\-\ mri\\ examination\\ of\\ the\\ sella\\ revealed\\ a\\ 2\\.6x1\\.5cm\\ enhancing\\ intrasellar\\ mass\\ encasing\\ the\\ left\\ internal\\ carotid\\ artery\\ and\\ expanding\\ the\\ posterior\\ sella\\ wall\\.\\ \\ in\\-111\\-octreotide\\ scan\\ showed\\ increase\\ uptake\\ in\\ the\\ intrasellar\\ mass\\.\\ \\ \ \(0\)\
\-\ note\\:\\ an\\ increased\\ uptake\\ of\\ octreotide\\,\\ a\\ somatostatin\\ analog\\ that\\ is\\ a\\ marker\\ of\\ neuroendocrine\\ neoplasms\\,\\ was\\ also\\ noted\\ in\\ the\\ thyroid\\ gland\\.\\ \\ this\\ was\\ due\\ to\\ a\\ coincident\\ papillary\\ thyroid\\ carcinoma\\.\ \(0\)\
\-\ pituitary\\ macroadenoma\\ secreting\\ tsh\\ and\\ gh\ \(0\)\
\-\ \\â\\€\\¢\\ pituitary\\ macroadenoma\\ \ \(0\)\
\-\ \\â\\€\\¢\\ craniopharyngioma\\ \ \(0\)\
\-\ \\â\\€\\¢\\ meningioma\\ \ \(0\)\
\-\ \\â\\€\\¢\\ aneurysm\\ \ \(0\)\
\-\ \\â\\€\\¢\\ rathke\\ cleft\\ cyst\ \(0\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ 55\\-year\\-old\\ caucasian\\ female\\ presents\\ with\\ 3\\-week\\ history\\ of\\ left\\ neck\\ mass\\.\\ \\ also\\ reports\\ 20lb\\ weight\\ loss\\ over\\ 3\\-month\\ period\\ and\\ onset\\ of\\ new\\ headache\\ over\\ prior\\ 3\\ weeks\\ associated\\ with\\ nausea\\,\\ emesis\\,\\ and\\ olfactory\\ hypersensitivity\\.\\ \\ no\\ visual\\ changes\\ were\\ noted\\.\ \(0\)\
\-\ tsh\\-secreting\\ adenomas\\ represent\\ a\\ small\\ percentage\\ of\\ pituitary\\ adenomas\\,\\ and\\ those\\ that\\ co\\-secrete\\ gh\\ are\\ even\\ more\\ rare\\,\\ with\\ fewer\\ than\\ 55\\ reported\\ in\\ the\\ medical\\ literature\\.\\ \\ the\\ elevated\\ thyroid\\ hormone\\ and\\ growth\\ hormone\\ levels\\ were\\ likely\\ contributing\\ to\\ the\\ patient\\â\\€\\™s\\ weight\\ loss\\,\\ coarse\\ facial\\ features\\,\\ and\\ thyroid\\ goiter\\,\\ and\\ the\\ patient\\â\\€\\™s\\ headaches\\ were\\ due\\ to\\ mass\\ effect\\ from\\ the\\ compression\\ of\\ the\\ optic\\ chiasm\\.\\ \\ \ \(0\)\
\-\ while\\ surgical\\ resection\\ remains\\ the\\ treatment\\ of\\ choice\\ for\\ pituitary\\ adenomas\\,\\ studies\\ have\\ demonstrated\\ that\\ somatostatin\\ analogs\\ can\\ effectively\\ reduce\\ autonomous\\ secretion\\ of\\ pituitary\\ hormones\\,\\ as\\ well\\ decrease\\ the\\ size\\ of\\ the\\ adenomas\\ by\\ approximately\\ 50\\%\\.\\ \\ due\\ to\\ the\\ invasive\\ nature\\ of\\ this\\ macroadenoma\\,\\ as\\ evidenced\\ by\\ the\\ encasement\\ of\\ the\\ left\\ internal\\ carotid\\ artery\\,\\ the\\ neoplasm\\ was\\ not\\ resectable\\ at\\ this\\ time\\.\\ \\ \\ therefore\\,\\ the\\ patient\\ was\\ started\\ on\\ octreotide\\ therapy\\ in\\ order\\ to\\ shrink\\ the\\ size\\ of\\ the\\ neoplasm\\ and\\ facilitate\\ a\\ more\\ optimal\\ surgical\\ outcome\\.\ \(0\)\
\-\ references\\:\ \(0\)\
\-\ abs\\ r\\,\\ et\\ la\\.\\ autonomously\\ functioning\\ thyroid\\ nodules\\ in\\ a\\ patient\\ with\\ a\\ thyrotropin\\-secreting\\ pituitary\\ adenoma\\:\\ possible\\ cause\\-\\-effect\\ relationship\\.\\ eur\\ j\\ endocrinol\\.\\ 1994\\ oct\\;131\\(4\\)\\:355\\-8\\.\\	\ \(0\)\
\-\ chanson\\ p\\,\\ et\\ al\\.\\ diagnosis\\ and\\ treatment\\ of\\ pituitary\\ adenomas\\.\\ minerva\\ endocrinol\\.\\ 2004\\ dec\\;29\\(4\\)\\:241\\-75\\	\ \(0\)\
\-\ grainger\\,\\ r\\.\\ g\\.\\,\\ allison\\,\\ d\\.\\,\\ adam\\,\\ a\\.\\,\\ \\&\\ dixon\\,\\ a\\.\\ k\\.\\ \\(eds\\.\\)\\.\\ \\(2008\\)\\.\\ grainger\\ and\\ allison\\'s\\ diagnostic\\ radiology\\:\\ a\\ textbook\\ of\\ medical\\ imaging\\ \\(5th\\ ed\\.\\)\\.\ \(0\)\
\-\ sen\\ o\\,\\ et\\ al\\.\\ silent\\ pituitary\\ macroadenoma\\ co\\-secreting\\ growth\\ hormone\\ and\\ thyroid\\ stimulating\\ hormone\\.\\ j\\ clin\\ neurosci\\.\\ 2005\\ apr\\;12\\(3\\)\\:318\\-20\\.\ \(0\)\
\-\ skoric\\ t\\,\\ et\\ al\\.\\ clinical\\ and\\ morphological\\ features\\ of\\ undifferentiated\\ monomorphous\\ gh\\/tsh\\-secreting\\ pituitary\\ adenoma\\.\\ eur\\ j\\ endocrinol\\.\\ 1999\\ jun\\;140\\(6\\)\\:528\\-37\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ pituitary\\:\\ 0\\.07281624148214168\ \(0\)\
\-\ adenomas\\:\\ 0\\.06145312126160964\ \(0\)\
\-\ macroadenoma\\:\\ 0\\.043566186967685876\ \(0\)\
\-\ gh\\:\\ 0\\.04342354840642005\ \(0\)\
\-\ thyroid\\:\\ 0\\.03789209754941727\ \(0\)\
\-\ endocrinol\\:\\ 0\\.037661690464018016\ \(0\)\
\-\ somatostatin\\:\\ 0\\.03444771590191626\ \(0\)\
\-\ octreotide\\:\\ 0\\.031233741339814505\ \(0\)\
\-\ hormone\\:\\ 0\\.029955032521881773\ \(0\)\
\-\ secretion\\:\\ 0\\.02935368674271328\ \(0\)\
\-\ grainger\\:\\ 0\\.02510779364267868\ \(0\)\
\-\ allison\\:\\ 0\\.02510779364267868\ \(0\)\
\-\ analogs\\:\\ 0\\.02296514393461084\ \(0\)\
\-\ autonomous\\:\\ 0\\.021711774203210025\ \(0\)\
\-\ et\\:\\ 0\\.02162224686319803\ \(0\)\
\-\ tsh\\:\\ 0\\.021519928071425935\ \(0\)\
\-\ effectively\\:\\ 0\\.020822494226543004\ \(0\)\
\-\ hormones\\:\\ 0\\.020822494226543004\ \(0\)\
\-\ facilitate\\:\\ 0\\.020458404471809206\ \(0\)\
\-\ intrasellar\\:\\ 0\\.020458404471809206\ \(0\)\
\-\ eur\\:\\ 0\\.020458404471809206\ \(0\)\
\-\ \\:\\:\\ 0\\.01921641881900667\ \(0\)\
\-\ optimal\\:\\ 0\\.019092615438489148\ \(0\)\
\-\ j\\:\\ 0\\.017896559658571426\ \(0\)\
\-\ t3\\:\\ 0\\.017062385032340553\ \(0\)\
\-\ al\\:\\ 0\\.016797039751512925\ \(0\)\
\-\ features\\:\\ 0\\.016720396929482583\ \(0\)\
\-\ \\,\\:\\ 0\\.01589950925758411\ \(0\)\
\-\ outcome\\:\\ 0\\.015771086112093324\ \(0\)\
\-\ coarse\\:\\ 0\\.015623858758185272\ \(0\)\
\-\ sella\\:\\ 0\\.015220086942367454\ \(0\)\
\-\ reduce\\:\\ 0\\.014919735324272716\ \(0\)\
\-\ a\\.\\:\\ 0\\.014807316022353472\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.0145318177891427\ \(0\)\
\-\ due\\:\\ 0\\.01409754035828649\ \(0\)\
\-\ choice\\:\\ 0\\.013666365592871899\ \(0\)\
\-\ brow\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ 427\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ 5\\.58\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ hgh\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ 362\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ 2\\.6x1\\.5cm\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ 3\\-week\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ tsh\\-secreting\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ co\\-secrete\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ autonomously\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ thyrotropin\\-secreting\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ \\:355\\-8\\.\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ chanson\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ \\:241\\-75\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ sen\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ co\\-secreting\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ \\:318\\-20\\.\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ skoric\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ gh\\/tsh\\-secreting\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ \\:528\\-37\\:\\ 0\\.013625221675373259\ \(0\)\
\-\ size\\:\\ 0\\.013283813932204503\ \(0\)\
\-\ invasive\\:\\ 0\\.01327273523003851\ \(0\)\
\-\ subunit\\:\\ 0\\.01255389682133934\ \(0\)\
\-\ unregulated\\:\\ 0\\.01255389682133934\ \(0\)\
\-\ in\\-111\\-octreotide\\:\\ 0\\.01255389682133934\ \(0\)\
\-\ 20lb\\:\\ 0\\.01255389682133934\ \(0\)\
\-\ 3\\-month\\:\\ 0\\.01255389682133934\ \(0\)\
\-\ minerva\\:\\ 0\\.01255389682133934\ \(0\)\
\-\ \\;\\:\\ 0\\.012521923885332882\ \(0\)\
\-\ nature\\:\\ 0\\.012503350230296239\ \(0\)\
\-\ decrease\\:\\ 0\\.012087306477675638\ \(0\)\
\-\ were\\:\\ 0\\.01199558786207061\ \(0\)\
\-\ visual\\:\\ 0\\.011974887175756396\ \(0\)\
\-\ igf\\-1\\:\\ 0\\.011927211955638931\ \(0\)\
\-\ analog\\:\\ 0\\.011927211955638931\ \(0\)\
\-\ coincident\\:\\ 0\\.011927211955638931\ \(0\)\
\-\ abs\\:\\ 0\\.011927211955638931\ \(0\)\
\-\ dixon\\:\\ 0\\.011927211955638931\ \(0\)\
\-\ neurosci\\:\\ 0\\.011927211955638931\ \(0\)\
\-\ morphological\\:\\ 0\\.011927211955638931\ \(0\)\
\-\ monomorphous\\:\\ 0\\.011927211955638931\ \(0\)\
\-\ carotid\\:\\ 0\\.011845167858603282\ \(0\)\
\-\ facial\\:\\ 0\\.011485786695957649\ \(0\)\
\-\ growth\\:\\ 0\\.011485786695957649\ \(0\)\
\-\ total\\:\\ 0\\.011374714024470592\ \(0\)\
\-\ gland\\:\\ 0\\.011249980498895421\ \(0\)\
\-\ surgical\\:\\ 0\\.011104925936639589\ \(0\)\
\-\ adenoma\\:\\ 0\\.011030894441440531\ \(0\)\
\-\ nodules\\:\\ 0\\.010950599274815306\ \(0\)\
\-\ fsh\\:\\ 0\\.010855887101605012\ \(0\)\
\-\ 55\\-year\\-old\\:\\ 0\\.010855887101605012\ \(0\)\
\-\ adam\\:\\ 0\\.010855887101605012\ \(0\)\
\-\ jun\\:\\ 0\\.010855887101605012\ \(0\)\
\-\ lh\\:\\ 0\\.010617632573278492\ \(0\)\
\-\ resectable\\:\\ 0\\.010617632573278492\ \(0\)\
\-\ shrink\\:\\ 0\\.010617632573278492\ \(0\)\
\-\ la\\:\\ 0\\.010617632573278492\ \(0\)\
\-\ uptake\\:\\ 0\\.010494539179889373\ \(0\)\
\-\ concentrations\\:\\ 0\\.010229202235904603\ \(0\)\
\-\ 3\\.6\\:\\ 0\\.010229202235904603\ \(0\)\
\-\ suppress\\:\\ 0\\.010229202235904603\ \(0\)\
\-\ fewer\\:\\ 0\\.010229202235904603\ \(0\)\
\-\ acth\\:\\ 0\\.010066357544006881\ \(0\)\
\-\ neuroendocrine\\:\\ 0\\.010066357544006881\ \(0\)\
\-\ stimulating\\:\\ 0\\.010066357544006881\ \(0\)\
\-\ 50\\:\\ 0\\.010049452910800014\ \(0\)\
\-\ tolerance\\:\\ 0\\.009919046601496333\ \(0\)\
\-\ encasing\\:\\ 0\\.009919046601496333\ \(0\)\
\-\ silent\\:\\ 0\\.009919046601496333\ \(0\)\
\-\ more\\:\\ 0\\.009909627400210971\ \(0\)\
\-\ secreting\\:\\ 0\\.009784562247571094\ \(0\)\
\-\ undifferentiated\\:\\ 0\\.009784562247571094\ \(0\)\
\-\ dtrs\\:\\ 0\\.009660848634474438\ \(0\)\
\-\ olfactory\\:\\ 0\\.009660848634474438\ \(0\)\
\-\ encasement\\:\\ 0\\.009660848634474438\ \(0\)\
\-\ 131\\:\\ 0\\.009660848634474438\ \(0\)\
\-\ apr\\:\\ 0\\.009660848634474438\ \(0\)\
\-\ eds\\:\\ 0\\.009546307719244574\ \(0\)\
\-\ weight\\:\\ 0\\.009468147712954761\ \(0\)\
\-\ prolactin\\:\\ 0\\.009439672678306473\ \(0\)\
\-\ effect\\:\\ 0\\.00935257574364527\ \(0\)\
\-\ 140\\:\\ 0\\.009339922259237583\ \(0\)\
\-\ was\\:\\ 0\\.009164861102445318\ \(0\)\
\-\ percentage\\:\\ 0\\.009157877381870686\ \(0\)\
\-\ neoplasm\\:\\ 0\\.008995847220747845\ \(0\)\
\-\ ft4\\:\\ 0\\.008995032689972962\ \(0\)\
\-\ evidenced\\:\\ 0\\.008995032689972962\ \(0\)\
\-\ elevated\\:\\ 0\\.008962338056751354\ \(0\)\
\-\ \\(\\:\\ 0\\.008931829690805075\ \(0\)\
\-\ 3\\.1\\:\\ 0\\.008919622853544164\ \(0\)\
\-\ 1994\\:\\ 0\\.008919622853544164\ \(0\)\
\-\ internal\\:\\ 0\\.008855875954803003\ \(0\)\
\-\ alpha\\:\\ 0\\.008847721747462414\ \(0\)\
\-\ contributing\\:\\ 0\\.008847721747462414\ \(0\)\
\-\ textbook\\:\\ 0\\.008847721747462414\ \(0\)\
\-\ \\)\\:\\ 0\\.008822722622730202\ \(0\)\
\-\ hypersensitivity\\:\\ 0\\.008779017323087092\ \(0\)\
\-\ oct\\:\\ 0\\.008779017323087092\ \(0\)\
\-\ dec\\:\\ 0\\.008713237393537175\ \(0\)\
\-\ expanding\\:\\ 0\\.00858952378044052\ \(0\)\
\-\ marker\\:\\ 0\\.00858952378044052\ \(0\)\
\-\ functioning\\:\\ 0\\.00858952378044052\ \(0\)\
\-\ 1\\.3\\:\\ 0\\.008531192516170277\ \(0\)\
\-\ r\\.\\:\\ 0\\.008531192516170277\ \(0\)\
\-\ jaw\\:\\ 0\\.00842074589486866\ \(0\)\
\-\ goiter\\:\\ 0\\.00842074589486866\ \(0\)\
\-\ g\\.\\:\\ 0\\.00842074589486866\ \(0\)\
\-\ resection\\:\\ 0\\.008237760913509177\ \(0\)\
\-\ rathke\\:\\ 0\\.008174896289567754\ \(0\)\
\-\ approximately\\:\\ 0\\.008172543513309375\ \(0\)\
\-\ initiated\\:\\ 0\\.008130093295946035\ \(0\)\
\-\ medical\\:\\ 0\\.008127696445335408\ \(0\)\
\-\ o\\:\\ 0\\.008044204808844317\ \(0\)\
\-\ treatment\\:\\ 0\\.008019862254718178\ \(0\)\
\-\ patient\\:\\ 0\\.00794366551081658\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.007894982193649014\ \(0\)\
\-\ artery\\:\\ 0\\.007865625941601851\ \(0\)\
\-\ chiasm\\:\\ 0\\.007848297999510246\ \(0\)\
\-\ relationship\\:\\ 0\\.007848297999510246\ \(0\)\
\-\ d\\.\\:\\ 0\\.007848297999510246\ \(0\)\
\-\ clin\\:\\ 0\\.007776396893428496\ \(0\)\
\-\ t4\\:\\ 0\\.007741662958572146\ \(0\)\
\-\ loss\\:\\ 0\\.007667586313658236\ \(0\)\
\-\ 2008\\:\\ 0\\.007641912539503257\ \(0\)\
\-\ nose\\:\\ 0\\.007610043471183727\ \(0\)\
\-\ s\\:\\ 0\\.007575788770060547\ \(0\)\
\-\ 1999\\:\\ 0\\.007488758130470443\ \(0\)\
\-\ all\\:\\ 0\\.007471169982786061\ \(0\)\
\-\ emesis\\:\\ 0\\.007459867662136358\ \(0\)\
\-\ this\\:\\ 0\\.007427644616028849\ \(0\)\
\-\ failed\\:\\ 0\\.0073763016323523155\ \(0\)\
\-\ 4\\:\\ 0\\.0073600368011717005\ \(0\)\
\-\ mass\\:\\ 0\\.0073475178172956075\ \(0\)\
\-\ k\\:\\ 0\\.007197272551169746\ \(0\)\
\-\ remarkable\\:\\ 0\\.007173309357141979\ \(0\)\
\-\ 2005\\:\\ 0\\.007126469558849355\ \(0\)\
\-\ literature\\:\\ 0\\.007103571435533835\ \(0\)\
\-\ 2004\\:\\ 0\\.007103571435533835\ \(0\)\
\-\ therapy\\:\\ 0\\.007062259030110087\ \(0\)\
\-\ glucose\\:\\ 0\\.007058768441912115\ \(0\)\
\-\ craniopharyngioma\\:\\ 0\\.00699390878333556\ \(0\)\
\-\ 29\\:\\ 0\\.006891514060706192\ \(0\)\
\-\ remains\\:\\ 0\\.006871824685470598\ \(0\)\
\-\ that\\:\\ 0\\.006843805542003817\ \(0\)\
\-\ 5th\\:\\ 0\\.006795483487125039\ \(0\)\
\-\ field\\:\\ 0\\.0067769731454763275\ \(0\)\
\-\ p\\:\\ 0\\.0067769731454763275\ \(0\)\
\-\ over\\:\\ 0\\.006725324853601121\ \(0\)\
\-\ neoplasms\\:\\ 0\\.006722736175134335\ \(0\)\
\-\ papillary\\:\\ 0\\.006705072039394577\ \(0\)\
\-\ painless\\:\\ 0\\.006636367615019255\ \(0\)\
\-\ order\\:\\ 0\\.006619658316558334\ \(0\)\
\-\ by\\:\\ 0\\.00659754669201642\ \(0\)\
\-\ cleft\\:\\ 0\\.0064468740723726825\ \(0\)\
\-\ suggesting\\:\\ 0\\.006417433276436524\ \(0\)\
\-\ 55\\:\\ 0\\.006402920540192568\ \(0\)\
\-\ serum\\:\\ 0\\.006374297591556962\ \(0\)\
\-\ caucasian\\:\\ 0\\.006304976778318396\ \(0\)\
\-\ noted\\:\\ 0\\.006260961942666441\ \(0\)\
\-\ therefore\\:\\ 0\\.0062386320415069065\ \(0\)\
\-\ remainder\\:\\ 0\\.006225698116204718\ \(0\)\
\-\ normal\\:\\ 0\\.006211495152700623\ \(0\)\
\-\ 3\\:\\ 0\\.00618539575488884\ \(0\)\
\-\ period\\:\\ 0\\.006175018328224824\ \(0\)\
\-\ \\%\\:\\ 0\\.006161734260729544\ \(0\)\
\-\ a\\:\\ 0\\.006129826921462153\ \(0\)\
\-\ optic\\:\\ 0\\.006113919659358309\ \(0\)\
\-\ t\\:\\ 0\\.006113919659358309\ \(0\)\
\-\ defects\\:\\ 0\\.006066722249991877\ \(0\)\
\-\ \\-\\-\\:\\ 0\\.006066722249991877\ \(0\)\
\-\ those\\:\\ 0\\.006009682749318846\ \(0\)\
\-\ r\\:\\ 0\\.005998523169761679\ \(0\)\
\-\ as\\:\\ 0\\.00599340420043645\ \(0\)\
\-\ can\\:\\ 0\\.005991413763428345\ \(0\)\
\-\ well\\:\\ 0\\.00597552072015039\ \(0\)\
\-\ to\\:\\ 0\\.005940669205543858\ \(0\)\
\-\ pe\\:\\ 0\\.0059332066175362035\ \(0\)\
\-\ started\\:\\ 0\\.005891147013942873\ \(0\)\
\-\ even\\:\\ 0\\.005880808546940096\ \(0\)\
\-\ represent\\:\\ 0\\.005800499831436679\ \(0\)\
\-\ smooth\\:\\ 0\\.005781058127871207\ \(0\)\
\-\ test\\:\\ 0\\.005642554018613577\ \(0\)\
\-\ mildly\\:\\ 0\\.005624990249447711\ \(0\)\
\-\ radiology\\:\\ 0\\.005581934678345754\ \(0\)\
\-\ ed\\:\\ 0\\.005581934678345754\ \(0\)\
\-\ oral\\:\\ 0\\.005565042760985336\ \(0\)\
\-\ increase\\:\\ 0\\.0055400460697247475\ \(0\)\
\-\ references\\:\\ 0\\.005491233748163234\ \(0\)\
\-\ levels\\:\\ 0\\.005451702307993761\ \(0\)\
\-\ limits\\:\\ 0\\.005443915918457505\ \(0\)\
\-\ free\\:\\ 0\\.005436168558606586\ \(0\)\
\-\ 12\\:\\ 0\\.005405561715799508\ \(0\)\
\-\ the\\:\\ 0\\.005341935266755247\ \(0\)\
\-\ reports\\:\\ 0\\.0053243901017601784\ \(0\)\
\-\ nausea\\:\\ 0\\.005317217954068521\ \(0\)\
\-\ diagnostic\\:\\ 0\\.005233651924284478\ \(0\)\
\-\ aneurysm\\:\\ 0\\.005220153191720715\ \(0\)\
\-\ also\\:\\ 0\\.005207479424019015\ \(0\)\
\-\ rare\\:\\ 0\\.005128825654827351\ \(0\)\
\-\ note\\:\\ 0\\.005097473767390712\ \(0\)\
\-\ meningioma\\:\\ 0\\.005078963425742001\ \(0\)\
\-\ used\\:\\ 0\\.005066745219394067\ \(0\)\
\-\ headaches\\:\\ 0\\.0050485971237577715\ \(0\)\
\-\ compression\\:\\ 0\\.004943968046831416\ \(0\)\
\-\ studies\\:\\ 0\\.0049327680336617614\ \(0\)\
\-\ reported\\:\\ 0\\.004814644282188272\ \(0\)\
\-\ including\\:\\ 0\\.004768807791333731\ \(0\)\
\-\ and\\:\\ 0\\.004729757492191212\ \(0\)\
\-\ palpable\\:\\ 0\\.004681021704172783\ \(0\)\
\-\ \\&\\:\\ 0\\.004638930281516896\ \(0\)\
\-\ new\\:\\ 0\\.004602454369088962\ \(0\)\
\-\ headache\\:\\ 0\\.004536298976144973\ \(0\)\
\-\ enlarged\\:\\ 0\\.004506369506003101\ \(0\)\
\-\ cause\\:\\ 0\\.004468721215690828\ \(0\)\
\-\ possible\\:\\ 0\\.0044481950832829555\ \(0\)\
\-\ left\\:\\ 0\\.004433254726149527\ \(0\)\
\-\ showed\\:\\ 0\\.004330453273452391\ \(0\)\
\-\ revealed\\:\\ 0\\.004238754080163977\ \(0\)\
\-\ onset\\:\\ 0\\.004169120905603014\ \(0\)\
\-\ while\\:\\ 0\\.00415556296731424\ \(0\)\
\-\ enhancing\\:\\ 0\\.0041421229256333215\ \(0\)\
\-\ examination\\:\\ 0\\.004105754305215711\ \(0\)\
\-\ clinical\\:\\ 0\\.004063848222667704\ \(0\)\
\-\ of\\:\\ 0\\.0039614893625282005\ \(0\)\
\-\ 6\\:\\ 0\\.003944544298879249\ \(0\)\
\-\ in\\:\\ 0\\.003907856848286754\ \(0\)\
\-\ neck\\:\\ 0\\.0038782737820996635\ \(0\)\
\-\ demonstrated\\:\\ 0\\.003875455923426534\ \(0\)\
\-\ wall\\:\\ 0\\.0038255936943411843\ \(0\)\
\-\ changes\\:\\ 0\\.0037852364393123035\ \(0\)\
\-\ weeks\\:\\ 0\\.003748497305875036\ \(0\)\
\-\ carcinoma\\:\\ 0\\.0037433194281543533\ \(0\)\
\-\ time\\:\\ 0\\.0037304501193806995\ \(0\)\
\-\ likely\\:\\ 0\\.0037253322502869496\ \(0\)\
\-\ scan\\:\\ 0\\.003697482937299812\ \(0\)\
\-\ however\\:\\ 0\\.0036775394986044365\ \(0\)\
\-\ cyst\\:\\ 0\\.0035492598702103594\ \(0\)\
\-\ than\\:\\ 0\\.003460662836040609\ \(0\)\
\-\ prior\\:\\ 0\\.0033912098488444566\ \(0\)\
\-\ for\\:\\ 0\\.0033807178453294363\ \(0\)\
\-\ metastatic\\:\\ 0\\.003324744055048053\ \(0\)\
\-\ physical\\:\\ 0\\.0032403481755506\ \(0\)\
\-\ increased\\:\\ 0\\.0032310429394121418\ \(0\)\
\-\ associated\\:\\ 0\\.003116634562453944\ \(0\)\
\-\ without\\:\\ 0\\.0031097575986988564\ \(0\)\
\-\ imaging\\:\\ 0\\.003094395401013296\ \(0\)\
\-\ posterior\\:\\ 0\\.003044263599230987\ \(0\)\
\-\ small\\:\\ 0\\.0030426202231547427\ \(0\)\
\-\ mri\\:\\ 0\\.003034429451181793\ \(0\)\
\-\ diagnosis\\:\\ 0\\.00303279649270544\ \(0\)\
\-\ \\'s\\:\\ 0\\.0029119731350340725\ \(0\)\
\-\ exam\\:\\ 0\\.0029014434929668285\ \(0\)\
\-\ have\\:\\ 0\\.002860027941831672\ \(0\)\
\-\ had\\:\\ 0\\.002849845161113923\ \(0\)\
\-\ female\\:\\ 0\\.0027152399867818137\ \(0\)\
\-\ presents\\:\\ 0\\.0026980591893476444\ \(0\)\
\-\ no\\:\\ 0\\.0026597964473069613\ \(0\)\
\-\ within\\:\\ 0\\.0025195230423277924\ \(0\)\
\-\ disease\\:\\ 0\\.0021587906355729583\ \(0\)\
\-\ \\.\\:\\ 0\\.0020849804817606775\ \(0\)\
\-\ be\\:\\ 0\\.0020367182741019\ \(0\)\
\-\ from\\:\\ 0\\.001957396774581472\ \(0\)\
\-\ not\\:\\ 0\\.0019085296317495138\ \(0\)\
\-\ an\\:\\ 0\\.001826375369837295\ \(0\)\
\-\ history\\:\\ 0\\.001824133752252061\ \(0\)\
\-\ are\\:\\ 0\\.0018004232960272051\ \(0\)\
\-\ at\\:\\ 0\\.0017894330028309629\ \(0\)\
\-\ is\\:\\ 0\\.0017381476920702492\ \(0\)\
\-\ on\\:\\ 0\\.0011188423684164266\ \(0\)\
\-\ with\\:\\ 0\\.0007233643034923631\ \(0\)\
